Download PDF
Int J Sports Med 2003; 24(5): 344-351
DOI: 10.1055/s-2003-40705
Physiology & Biochemistry
© Georg Thieme Verlag Stuttgart · New York

Prospective Echocardiographic Assessment of Androgenic-Anabolic Steroids Effects on Cardiac Structure and Function in Strength Athletes

F.  Hartgens1 , E.  C.  Cheriex2 , H.  Kuipers3
  • 1Netherlands Centre for Doping Affairs, Capelle aan den IJssel, The Netherlands
  • 2Department of Cardiology, University Hospital Maastricht, Maastricht, The Netherlands
  • 3Department of Movement Sciences, Maastricht University, Maastricht, The Netherlands
Further Information

Publication History

Accepted after revision: January 25, 2003

Publication Date:
17 July 2003 (online)

Also available at
    Permissions and Reprints

Abstract

Since the abuse of androgenic-anabolic steroids (AAS) has been associated with the occurrence of serious cardiovascular disease in young athletes, we performed two studies to investigate the effects of short-term AAS administration on heart structure and function in experienced male strength athletes, with special reference to dose and duration of drug abuse. In Study 1 the effects of AAS were assessed in 17 experienced male strength athletes (age 31 ± 7 y) who self-administered AAS for 8 or 12 - 16 weeks and in 15 non-using strength athletes (age 33 ± 5 y) in a non-blinded design. In Study 2 the effects of administration of nandrolone decanoate (200 mg/wk i. m.) for eight weeks were investigated in 16 bodybuilders in a randomised double blind, placebo controlled design. In all subjects M-mode and two-dimensional Doppler-echocardiography were performed at baseline and after 8 weeks AAS administration. In the athletes of Study 1 who used AAS for 12 - 16 weeks a third echocardiogram was also made at the end of the AAS administration period. Echocardiographic examinations included the determination of the aortic diameter (AD), left atrium diameter (LA), left ventricular end diastolic diameter (LVEDD), interventricular septum thickness (IVS), posterior wall end diastolic wall thickness (PWEDWT), left ventricular mass (LVM), left ventricular mass index (LVMI), ejection fraction (EF) and right ventricular diameter (RVD). For assessment of the diastolic function measurements of E and A peak velocities and calculation of E/A ratio were used. In addition, acceleration and deceleration times of the E-top (ATM and DT, respectively) were determined. For evaluation of factors associated with stroke volume the aorta peak flow (AV) and left ventricular ejection times (LVET) were determined. In Study 1 eight weeks AAS self-administration did not result in changes of blood pressure or cardiac size and function. Additionally, duration of AAS self-administration did not have any impact on these parameters. Study 2 revealed that eight weeks administration of nandrolone decanoate did not induce significant alterations in blood pressure and heart morphology and function. Short-term administration of AAS for periods up to 16 weeks did not lead to detectable echocardiographic alterations of heart morphology and systolic and diastolic function in experienced strength athletes. The administration regimen used nor the length of AAS abuse did influence the results. Moreover, it is concluded that echocardiographic evaluation may provide incomplete assessment of the actual cardiac condition in AAS users since it is not sensitive enough to detect alterations at the cellular level. Nevertheless, from the present study no conclusions can be drawn of the cardiotoxic effects of long term AAS abuse.

Key words

Androgenic-anabolic steroids - nandrolone decanoate - echocardiography - blood pressure - heart morphology - heart function - doping

References

  • 1 Appell HJ, Heller-Umpfenbach B, Feraudi M, Weicker H. Ultrastructural and morphometric investigations on the effects of training and administration of anabolic steroids on the myocardium of guinea pigs.  Int J Sports Med. 1983;  4 268-274
    PubMedGoogle Scholar
  • 2 Bahrke M S, Yesalis C R, Wright J E. Psychological and behavioural effects of endogenous testosterone and anabolic-androgenic steroids. An update.  Sports Med. 1996;  22 367-390
    PubMedGoogle Scholar
  • 3 Behrendt H. Effect of anabolic steroids on rat heart muscle cells. I. Intermediate filaments.  Cell Tissue Res. 1977;  180 303-315
    PubMedGoogle Scholar
  • 4 Behrendt H, Boffin H. Myocardial cell lesions caused by an anabolic hormone.  Cell Tissue Res. 1977;  181 423-426
    PubMedGoogle Scholar
  • 5 Brown B S, Pilch A H. The effects of exercise and dianabol upon selected performances and physiological parameters in the male rat.  Med Sci Sports. 1972;  4 159-165
    PubMedGoogle Scholar
  • 6 de Piccoli B, Giada F, Benettin A, Sartori F, Piccolo E. Anabolic steroid use in body builders: an echocardiographic study of left ventricle morphology and function.  Int J Sports Med. 1991;  12 408-412
    Article in Thieme ConnectPubMedGoogle Scholar
  • 7 Dickerman R D, Schaller F, Zachariah N Y, McConathy W J. Left ventricular size and function in elite bodybuilders using anabolic steroids.  Clin J Sport Med. 1997;  7 90-93
    CrossrefPubMedGoogle Scholar
  • 8 Ferenchick G S, Adelman S. Myocardial infarction associated with anabolic steroid use in a previously healthy 37-year-old weight lifter.  Am Heart J. 1992;  124 507-508
    CrossrefPubMedGoogle Scholar
  • 9 Friedl K E. Effects of anabolic steroids on physical health. In: Yesalis CE (ed) Anabolic Steroids in Sport and Exercise. Champaign; Human Kinetics 2000 2nd ed: 175-224
    Google Scholar
  • 10 Hartgens F, Kuipers H, Wijnen J, Keizer H A. Body composition, cardiovascular risk factors and liver function in long term androgenic-anabolic steroids using bodybuilders three months after drug withdrawal.  Int J Sports Med. 1996;  17 429-433
    Article in Thieme ConnectPubMedGoogle Scholar
  • 11 Huie M J. An acute myocardial infarction occurring in an anabolic steroid user (case study).  Med Sci Sports Exerc. 1994;  26 408-413
    PubMedGoogle Scholar
  • 12 Ishak K G, Zimmerman H J. Hepatotoxic effects of the anabolic/androgenic steroids.  Semin Liver Dis. 1987;  7 230-236
    PubMedGoogle Scholar
  • 13 Kennedy M C, Lawrence C. Anabolic steroid abuse and cardiac death.  Med J Aust. 1993;  158 346-348
    PubMedGoogle Scholar
  • 14 Koert A, van Kleij R. Handel in doping. Nieuwegein; Arko Uitgeverij 1998
    Google Scholar
  • 15 Kutscher E C, Lund B C, Perry P J. Anabolic steroids: a review for the clinician.  Sports Med. 2002;  32 285-296
    CrossrefPubMedGoogle Scholar
  • 16 McKillop G, Todd IC, Ballantyne D. Increased left ventricular mass in a bodybuilder using anabolic steroids.  Br J Sports Med. 1986;  20 151-152
    PubMedGoogle Scholar
  • 17 Melchert R B, Welder A A. Cardiovascular effects of androgenic-anabolic steroids. Med Sci.  Sports Exerc. 1995;  27 1252-1262
    PubMedGoogle Scholar
  • 18 Mochizucki R M, Richter K J. Cardiomyopathy and cerebrovascular accident associated with anabolic-androgenic steroid use.  Physician Sportsmed. 1988;  16 109-114
    PubMedGoogle Scholar
  • 19 Moore L G, McMurtry I F, Reeves J T. Effects of sex hormones on cardiovascular and hematologic responses to chronic hypoxia in rats.  Proc Soc Exp Biol Med. 1978;  158 658-662
    PubMedGoogle Scholar
  • 20 Morano I, Gerstner J, Ruegg J C, Ganten U, Ganten D, Vosberg V P. Regulation of myosin heavy chain expression in the hearts of hypertensive rats by testosterone.  Circ Res. 1990;  66 1585-1590
    PubMedGoogle Scholar
  • 21 Nieminen M S, Ramo M P, Viitasalo M, Heikkila P, Karjalainen J, Mantysaari M, Heikkila J. Serious cardiovascular side effects of large doses of anabolic steroids in weight lifters.  Eur Heart J. 1996;  17 1576-1583
    CrossrefPubMedGoogle Scholar
  • 22 Palatini P, Giada F, Garavelli G, Sinisi F, Mario L, Michieletto M, Baldo E G. Cardiovascular effects of anabolic steroids in weight-trained subjects.  J Clin Pharmacol. 1996;  36 1132-1140
    CrossrefPubMedGoogle Scholar
  • 23 Pärssinen M, Seppala T. Steroid use and long-term health risks in former athletes.  Sports Med. 2002;  32 83-94
    PubMedGoogle Scholar
  • 24 Pelliccia A, Maron B J. Outer limits of the athlete's heart, the effect of gender, and relevance to the differential diagnosis with primary cardiac diseases.  Cardiol Clin. 1997;  15 381-396
    PubMedGoogle Scholar
  • 25 Pesola M K. Reversibility of the haemodynamic effects of anabolic steroids in rats.  Eur J Appl Physiol. 1988;  58 125-131
    CrossrefPubMedGoogle Scholar
  • 26 Ramo P, Kettunen R, Hirvonen L. The effects of anabolic steroids and endurance training on systolic time intervals in the dog.  Acta Physiol Scand. 1987;  129 543-548
    PubMedGoogle Scholar
  • 27 Sachtleben T R, Berg K E, Elias B A, Cheatham J P, Felix G L, Hofschire P J. The effects of anabolic steroids on myocardial structure and cardiovascular fitness.  Med Sci Sports Exerc. 1993;  25 1240-1245
    PubMedGoogle Scholar
  • 28 Salke R C, Rowland T W, Burke E J. Left ventricular size and function in body builders using anabolic steroids.  Med Sci Sports Exerc. 1985;  17 701-704
    PubMedGoogle Scholar
  • 29 Spataro A, Caselli G, Pelliccia A, Biffi A, Iranquilli C, Fernando F, Marcello G. Anabolic steroids do not increase left ventricular mass index in well trained athletes (abstract).  Med Sci Sports Exerc. 1992;  24 S29
    PubMedGoogle Scholar
  • 30 Spirito P, Pelliccia A, Proschan M A, Granata M, Spataro A, Bellone P, Caselli G, Biffi A, Vecchio C, Maron B J. Morphology of the “athlete's heart” assessed by echocardiography in 947 elite athletes representing 27 sports.  Am J Cardiol. 1994;  74 802-806
    CrossrefPubMedGoogle Scholar
  • 31 Sullivan M L, Martinez C M, Gallagher E J. Atrial fibrillation and anabolic steroids.  J Emerg Med. 1999;  17 851-857
    CrossrefPubMedGoogle Scholar
  • 32 Tagarakis C V, Bloch W, Hartmann G, Hollmann W, Addicks K. Anabolic steroids impair the exercise-induced growth of the cardiac capillary bed.  Int J Sports Med. 2000;  21 412-418
    Article in Thieme ConnectPubMedGoogle Scholar
  • 33 Tagarakis C V, Bloch W, Hartmann G, Hollmann W, Addicks K. Testosterone-propionate impairs the response of the cardiac capillary bed to exercise.  Med Sci Sports Exerc. 2000;  32 946-953
    PubMedGoogle Scholar
  • 34 Thomas L R, Douglas P S. Echocardiographic findings in athletes. In: Thompson PD (ed) Exercise and Sports Cardiology. New York; McGraw-Hill 2001: 43-70
    Google Scholar
  • 35 Thompson P D, Sadaniantz A, Cullinane E M, Bodziony K S, Catlin D H, Torek B G, Douglas P S. Left ventricular function is not impaired in weight-lifters who use anabolic steroids.  J Am Coll Cardiol. 1992;  19 278-282
    PubMedGoogle Scholar
  • 36 Urhausen A, Holpes R, Kindermann W. One- and two-dimensional echocardiography in bodybuilders using anabolic steroids.  Eur J Appl Physiol. 1989;  58 633-640
    CrossrefPubMedGoogle Scholar
  • 37 Yeater R, Reed C, Ullrich I, Morise A, Borsch M. Resistance trained athletes using or not using anabolic steroids compared to runners: Effects on cardiorespiratory variables, body composition, and plasma lipids.  Br J Sports Med. 1996;  30 11-14
    PubMedGoogle Scholar
  • 38 Yesalis C. Anabolic steroids in sport and exercise. Champaign, IL; Human Kinetics 2000 2nd ed
    Google Scholar
  • 39 Zuliani U, Bernardini B, Catapano A, Campana M, Cerioli G, Spattini M. Effects of anabolic steroids, testosterone, and HGH on blood lipids and echocardiographic parameters in body builders.  Int J Sports Med. 1989;  10 62-66
    Article in Thieme ConnectPubMedGoogle Scholar

F. Hartgens, M.D., Ph.D

University Hospital Maastricht and Sports Medicine Center Maastricht

PO Box 1146 · 6200 BC Maastricht · The Netherlands ·

Phone: +31-43-3623751

Fax: +31-43-3623751

Email: fhartgens@wxs.nl